Surveys - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll
Poll archive button
What does your company place the most emphasis on when analyzing tablet powder properties?
Particle characteristics:
19%
Bulk powder properties:
5%
Blend uniformity:
25%
We consider these properties equally:
51%
Other Surveys
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Negative impacts on drug development
Pharmaceutical business challenges
Manufacturing challenges
Continuous manufacturing
High potency processing
US Drug Quality and Security Act
Operational Excellence
Job security
QbD in sterile manufacturing
Drug Delivery Types
Anticounterfeiting
Social Media Tools
Threats to production
Utility of Solid-Dosage Equipment, Process Control
Application of QbD
Benefit of Applying QbD Principles
INTERPHEX 2013
Reputation of the Pharma Industry
Biosimilars
PAT Advances
Regulatory Enforcement
Industry Changes
Tablet Splitting
Trade Shows
Patent Cliff
FDA confidentiality
Preventing counterfeiting
European Pharmacovigilance Activities
Generic Drug User Fees Amendments of 2012
European Legislation
Drug Settlements
Emerging Markets
Energy Efficiency
Affordable Care Act
Drug Shortages
Transparency
Significant changes
Quality Management
Analytical equipment
DTC Advertising
Biologics Manufacturing
Sterile manufacturing
Social Media
API Manufacturing
Lyophilization Advances
Injection technologies
Oral drug delivery
Generic-Drug User Fees
Solid Dosage Innovation
Small-Molecule API Outsourcing
USP Monographs
Anticounterfeiting Solutions
FDA's Enforcement Strategy
Quality by Design and APIs
Outsourcing Biologics
FDA Biosimilars Pathway
Highly potent APIs
Biosimilars
Emerging markets
Strategies for Emerging Markets
Atypical actives
Shared audits
Continuous processing
Carbon Footprints
Immediate-release drug delivery
QbD and CMC
INTERPHEX 2011
FDA Transparency
Tableting equipment
Outsourcing Levels
FDA Recalls
Granulation Techniques
Pharma Forecast for 2011
Needleless devices
Trade Show Attendance
Regulation of excipients
Generic-Drug User Fees
Cleanroom Challenges
Small-Molecule Outsourcing
Pharma packaging
Recall News
Single-use technologies
Pay-to-Delay
Outsourcing concerns
Outsourcing
Green Manufacturing Efforts
Biosimilars: Threat or Opportunity?
Expanding FDA's Power
Anticounterfeiting solutions
Novel Excipients
Tablet manufacture
Equipment Purchasing
Healthcare Reform and Pharma
PharmTech Poll: Recession
Ingredient Suppliers
FDA Spending
PharmTech Poll: CMO Market

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here